Palvella Therapeutics (PVLA) Change in Accured Expenses (2013 - 2026)
Palvella Therapeutics (PVLA) reported Change in Accured Expenses of -$900000.0 for Q1 2026, up 69.07% year-over-year from -$532317.1 in Q1 2025, and down 408.22% on a QoQ basis from $292000.0 in Q4 2025.
Palvella Therapeutics (PVLA) has 8 years of Change in Accured Expenses data on file, last reported at -$900000.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 69.07% year-over-year to -$900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $710000.0 (up 133.08% YoY) and the FY2025 annual result came in at -$1.3 million, down 223.81% from the prior year.
- Change in Accured Expenses fell to -$900000.0 in Q1 2026 per PVLA's latest filing, from $292000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $801000.0 in Q3 2025 and bottomed at -$2.9 million in Q1 2025.
- The 3-year median for Change in Accured Expenses is $292000.0 (2025), against an average of -$127777.8.
- Peak annual rise in Change in Accured Expenses reached 181.56% in 2025, while the deepest fall reached 1117.48% in 2025.
- Tracing PVLA's Change in Accured Expenses over 3 years: stood at -$358000.0 in 2024, then soared by 181.56% to $292000.0 in 2025, then slumped by 408.22% to -$900000.0 in 2026.
- Per Business Quant, the three latest PVLA Change in Accured Expenses figures stand at -$900000.0 (Q1 2026), $292000.0 (Q4 2025), and $801000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | -900,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -900,000.00 |
| Mar 31, 2026 | -900,000.00 |
| Dec 31, 2025 | 292,000.00 |
| Dec 31, 2025 | 292,000.00 |
| Sep 30, 2025 | 801,000.00 |
| Sep 30, 2025 | 801,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Jun 30, 2025 | 517,000.00 |
| Mar 31, 2025 | -2.91 Mn |
| Mar 31, 2025 | -2.91 Mn |
| Dec 31, 2024 | -358,000.00 |
| Dec 31, 2024 | -358,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Sep 30, 2024 | 383,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Jun 30, 2024 | 739,000.00 |
| Mar 31, 2024 | 286,000.00 |
| Mar 31, 2024 | 286,000.00 |
| Dec 31, 2017 | 1.01 Mn |
| Dec 31, 2017 | 1.01 Mn |
| Sep 30, 2017 | -1.29 Mn |
| Sep 30, 2017 | -1.29 Mn |
| Jun 30, 2017 | 3.14 Mn |
| Jun 30, 2017 | 3.14 Mn |
| Mar 31, 2017 | -805,903.00 |
| Mar 31, 2017 | -805,903.00 |
| Dec 31, 2016 | 923,955.00 |
| Dec 31, 2016 | 923,955.00 |
| Sep 30, 2016 | 558,137.00 |
| Sep 30, 2016 | 558,137.00 |
| Jun 30, 2016 | 37,871.00 |
| Jun 30, 2016 | 37,871.00 |
| Mar 31, 2016 | 543,037.00 |
| Mar 31, 2016 | 543,037.00 |
| Dec 31, 2015 | 365,748.00 |
| Dec 31, 2015 | 365,748.00 |
| Sep 30, 2015 | 160,068.00 |
| Sep 30, 2015 | 160,068.00 |
| Jun 30, 2015 | 238,528.00 |
| Jun 30, 2015 | 238,528.00 |
| Mar 31, 2015 | -208,047.00 |
| Mar 31, 2015 | -208,047.00 |
| Sep 30, 2014 | -450,672.00 |
| Sep 30, 2014 | -450,672.00 |
| Jun 30, 2014 | -422,410.00 |
| Jun 30, 2014 | -422,410.00 |
| Mar 31, 2014 | -410,902.00 |
| Mar 31, 2014 | -410,902.00 |
| Dec 31, 2013 | 1,250.00 |
| Dec 31, 2013 | 1,250.00 |
| Sep 30, 2013 | 1,250.00 |
| Sep 30, 2013 | 1,250.00 |